Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Will these 20 dividend-paying stocks have a good opportunity for growth as the Fed is about to cut interest rates?
With the Fed cutting interest rates, not only banks and other financial companies will benefit, but non-financial giants like delta air lines and unitedhealth may also benefit from it.
Homebuilder Stocks Outperform Ahead Of Potential Rate Cuts — But What's Next?
Quebecor Reportedly Made Buyout Offer to Rival Corus but Did Not Hear Back
Live On CNBC, Stephanie Link Announces Bought More Chipotle Mexican Grill, Bought Exxon Mobil
How to view the "historically pessimistic" oil price, goldman sachs: short but long!
Goldman Sachs expects that Brent crude oil will recover to $77 per barrel in the fourth quarter of this year, as the market's overly pessimistic sentiment towards oil demand improves and the OECD inventory remains slightly below normal levels, providing some support for oil prices. However, over time, the market's pessimistic expectations for supply and demand balance are gradually increasing, putting further pressure on oil prices next year.
Wall Street's Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 7% Dividend Yields
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
A Closer Look at Exxon Mobil's Options Market Dynamics
Homebuilders Are Seeing an Uptick, Here Are the Best Performing - JPM
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Oil prices rebounded before the Federal Reserve interest rate decision, and it is feared that the bulls will have a difficult time causing a major storm.
Nearly 20% of crude oil production in the Gulf of Mexico in the United States has been halted, and with the imminent interest rate cut by the Federal Reserve, it has provided support for oil prices, but the market may still remain cautious.
What the Options Market Tells Us About AT&T
Altria Group Unusual Options Activity
Citi Says DirecTV-Dish Merger Has 'a High Degree of Industrial Logic'
Exxon Mobil Analyst Ratings
Don't just focus on the polls! The trend of the US stock market is the compass for the US presidential election. Here is an investment guide for you to check out.
Analysts have found that since 1984, as long as the S&P 500 index rises accumulatively between August and October, the ruling party will win the election; on the contrary, if the S&P 500 index drops during this period, the challenger will win.